MSD

News

Update: MSD confirms $3bn takeover of EyeBio

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular

News

AstraZeneca throws its hat into the oral PCSK9 ring

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

News

MSD’s maternal health initiative passes big milestone

A $650 million programme set up by pharma group MSD to help prevent maternal mortality and improve health equity around the world has reached over 30 million women, easily

News

MSD leaps on FDA approval of PAH drug sotatercept

MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather th

News

UK access disparity resolved as NICE backs RCC therapy

Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab

Update: MSD confirms $3bn takeover of EyeBio

AstraZeneca throws its hat into the oral PCSK9 ring

MSD has another TIGIT programme setback

MSD’s maternal health initiative passes big milestone

MSD leaps on FDA approval of PAH drug sotatercept

UK access disparity resolved as NICE backs RCC therapy

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

MSD

Editor's Picks